NBIX
Neurocrine Biosciences Inc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science.
Did you know?
Price sits at 48% of its 52-week range.
Current Price
$131.78
+0.08%GoodMoat Value
$213.39
61.9% undervaluedProfile
Valuation (TTM)
Market Cap$13.14B
P/E27.45
EV—
P/B4.04
Shares Out99.71M
P/Sales4.59
Revenue$2.86B
EV/EBITDA15.84
Neurocrine Biosciences Inc (NBIX) Stock Analysis
Market Cap$13.14B
Current Price$131.78
P/E Ratio27.45
Forward P/E—
PEG Ratio0.55
EPS$4.67
Book Value$32.63
P/B Ratio4.04
NBIX Financial Charts
NBIX 52-Week Range
$109.75
$155.63
50-Day MA: $130.25200-Day MA: $137.33
Did you know?
Price sits at 48% of its 52-week range.
Neurocrine Biosciences Inc (NBIX) Financial Summary
Neurocrine Biosciences Inc (NBIX) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ. The stock currently trades at $131.78 with a market capitalization of $13.14B.
Key valuation metrics include a P/E ratio of 27.45, price-to-book ratio of 4.04, and EPS of $4.67. The company reports a profit margin of 16.7% and return on equity of 14.7%.
NBIX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $13.14B |
| P/E Ratio | 27.45 |
| EPS | $4.67 |
| P/B Ratio | 4.04 |
| P/S Ratio | 4.59 |
| EV/EBITDA | 15.84 |
| Profit Margin | 16.7% |
| Return on Equity | 14.7% |
| Debt/Equity | 0.13 |
Neurocrine Biosciences Inc (NBIX) Valuation
Based on GoodMoat's DCF model, Neurocrine Biosciences Inc has a fair value estimate of $213.39. At the current price of $131.78, the stock appears 38.2% undervalued relative to our intrinsic value estimate.
NBIX Quality Indicators
Neurocrine Biosciences Inc maintains a profit margin of 16.7% and an operating margin of 21.6%. Return on equity stands at 14.7%. The current ratio is 3.39. Debt-to-equity ratio is 0.13.
About Neurocrine Biosciences Inc
Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science.
NBIX Free Cash Flow
Neurocrine Biosciences Inc generated $748.70M in trailing twelve-month free cash flow, representing an FCF yield of 5.70%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
NBIX Shares Outstanding
Neurocrine Biosciences Inc has 0.10 billion shares outstanding at a share price of $131.78, giving it a market capitalization of $13.14B.